Open AccessThe outcomes of children with acute myeloid leukemia treated in accordance with the AML–MM-2006 protocol
Author(s) -
И. И. Калинина,
D. A. Venyov,
Yu. V. Olshanskaya,
M. N. Sadovskaya,
О. В. Горонкова,
T.Yu. Salimova,
У. Н. Петрова,
Д. Д. Байдильдина,
Е.В. Сунцова,
Д. А. Евсеев,
V.E. Matveev,
К. С. Антонова,
И. Г. Хамин,
М. Э. Дубровина,
Elena Zerkalenkova,
Marina Gaskova,
Alexander Popov,
Svetlana Kashpor,
А. И. Манджиева,
T. V. Konyukhova,
L. A. Khachatryan,
Dmitry Litvinov,
Dmitry Balashov,
Anna Shcherbina,
Michael Maschan,
Galiovichkova,
Alexei Maschan
Publication year - 2022
Publication title -
voprosy gematologii/onkologii i immunopatologii v pediatrii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 3
eISSN - 2414-9314
pISSN - 1726-1708
DOI - 10.24287/1726-1708-2022-21-1-20-35
Subject(s) - medicine , hematology , myeloid leukemia , hematopoietic stem cell transplantation , transplantation , cohort , myeloid , chemotherapy , oncology
Over the past years, the outcomes of patients with acute myeloid leukemia (AML) have significantly improved due to the use of intensive chemotherapy, more effective supportive therapy, and the availability of allogeneic hematopoietic stem cell transplantation. This article presents the outcomes of children with AML treated in accordance with the AML-MM-2006 protocol. Our study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included 233 patients with a median age of 6.5 years (7 days – 18 years) who were stratified into the following risk groups: standard risk, intermediate risk, and high risk. The 5-year event-free survival (EFS) was 0.64 ± 0,14, 0.49 ± 0.05, and 0.43 ± 0.05 for standard-risk (n = 12), intermediate-risk (n = 106), and high-risk (n = 115) patients, respectively (p = 0.14), while the 5-year overall survival (OS) was 1.0 year, 0.7 ± 0.05 and 0.55 ± 0.05, respectively (p = 0.001). The OS in the entire cohort was 0.68 ± 0.032. Factors associated with poor prognosis included hyperleukocytosis, the presence of extramedullary lesions, and age < 1 year. The overall survival rates in these patient groups were 0.55 ± 0.08, 0.39 ± 0.09 and 0.49 ± 0.08, respectively. The worst prognosis was for patients with monosomy 7 and t(7;12) whose OS rates were 0.25 ± 0.2 and 0.4 ± 0.2, respectively. For non-responders and patients with relapsed AML, the OS was 0.33 ± 0.08 and 0.54 ± 0.06, respectively. Early death (before remission could be achieved) occurred in 4% of patients, and 3.8% of patients died in first remission. Sixtytwo percent of deceased patients died of disease progression. In the entire cohort of patients, the five-year EFS was 0.53 ± 0.047, the cumulative risk of relapse after 3 years of remission was 40%, the confidence interval was 23–89%.